Polymorphism in cytochrome P450 2A6 and glutathione S-transferase P1 modifies head and neck cancer risk and treatment outcome

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 669, Issue 1-2, 2009, Pages 36-41

  Ruwali, Munindra ^a   Pant, Mohan C ^b   Shah, Parag P ^a   Mishra, Bhartendu N ^c   Parmar, Devendra ^a  

^a CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

^b KING GEORGE'S MEDICAL UNIVERSITY   (India)

^c INSTITUTE OF ENGINEERING AND TECHNOLOGY   (India)

Author keywords

Cytochrome P450 2A6; HNSCC; Polymorphism; Risk; Tobacco

Indexed keywords

CISPLATIN; CYTOCHROME P450 2A6; FLUOROURACIL; GLUTATHIONE TRANSFERASE P1;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CASE CONTROL STUDY; CIGARETTE SMOKING; CONTROLLED STUDY; DNA POLYMORPHISM; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RISK ASSESSMENT; SMOKING; SQUAMOUS CELL CARCINOMA; TOBACCO; TREATMENT RESPONSE; WILD TYPE;

ARYL HYDROCARBON HYDROXYLASES; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; RISK FACTORS; SMOKING; TREATMENT OUTCOME;

NICOTIANA TABACUM;

EID: 70349122530     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2009.04.007     Document Type: Article

References (39)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55 (2005) 74-108
2. Hashibe M., Brennan P., Strange R.C., Bhisey R., Cascorbi I., Lazarus P., Oude Ophuis M.B., Benhamou S., Foulkes W.D., Katoh T., Coutelle C., Romkes M., Gaspari L., Taioli E., and Boffetta P. Meta- and pooled analyses of GSTM1, GSTT1, GSTP1 and CYP1A1 genotypes and risk of head and neck cancer. Cancer Epidemiol. Biomarkers Prev. 12 (2003) 1509-1517
3. Brennan P., and Boffetta P. Mechanistic considerations in the molecular epidemiology of head and neck cancer. IARC Sci. Publ. 157 (2004) 393-414
4. A.P. Singh, P.P. Shah, M. Ruwali, N. Mathur, M.C. Pant, D. Parmar, Polymorphism in cytochrome P4501A1 is significantly associated with head and neck cancer risk, Cancer Invest., in press.
5. Singh A.P., Shah P.P., Mathur N., Buters J.T.M., Pant M.C., and Parmar D. Genetic polymorphisms in cytochrome P4501B1 and susceptibility to head and neck cancer. Mutat. Res. 639 (2008) 11-19
6. Singh M., Shah P.P., Singh A.P., Ruwali M., Mathur N., Pant M.C., and Parmar D. Association of genetic polymorphisms in glutathione S-transferases and susceptibility to head and neck cancer. Mutat. Res. 638 (2008) 184-194
7. Mwenifumbo J.C., Lessov-Schlaggar C.N., Zhou Q., Krasnow R.E., Swan G.E., Benowitz N.L., and Tyndale R.F. Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism. Clin. Pharmacol. Ther. 83 (2008) 115-121
8. Xu C., Goodz S., Sellers E.M., and Tyndale R.F. CYP2A6 genetic variation and potential consequences. Adv. Drug Deliv. Rev. 54 (2002) 1245-1256
9. Kamataki T., Fujieda M., Kiyotani K., Iwano S., and Kunitoh H. Genetic polymorphism of CYP2A6 as one of the potential determinants of tobacco-related cancer risk. Biochem. Biophys. Res. Commun. 338 (2005) 306-310
10. Miyamoto M., Umetsu Y., Dosaka-Akita H., et al. CYP2A6 gene deletion reduces susceptibility to lung cancer. Biochem. Biophys. Res. Commun. 261 (1999) 658-660
11. London S.J., Idle J.R., Daly A.K., and Coetzee G.A. Genetic variation of CYP2A6, smoking, and risk of cancer. Lancet 353 (1999) 898-899
12. Tan W., Chen G.F., Xing D.Y., Song C.Y., Kadlubar F.F., and Lin D.X. Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population. Int. J. Cancer 95 (2001) 96-101
13. Topcu Z., Chiba I., Fujieda M., Shibata T., Ariyoshi N., Yamazaki H., Sevgican F., Muthumala M., Kobayashi H., and Kamataki T. CYP2A6 gene deletion reduces oral cancer risk in betel quid chewers in Sri Lanka. Carcinogenesis 23 (2002) 595-598
14. Ariyoshi N., Miyamoto M., Umetsu Y., Kunitoh H., Dosaka-Akita H., Sawamura Y., Yokota J., Nemoto N., Sato K., and Kamataki T. Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. Cancer Epidemiol. Biomarkers Prev. 11 (2002) 890-894
15. Fujieda M., Yamazaki H., Saito T., Kiyotani K., Gyamfi M.A., Sakurai M., Dosaka-Akita H., Sawamura Y., Yokota J., Kunitoh H., and Kamataki T. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis 12 (2004) 2451-2458
16. Tiwawech D., Srivatanakul P., Karalak A., and Ishida T. Cytochrome P450 2A6 polymorphism in nasopharyngeal carcinoma. Cancer Lett. 241 (2006) 135-141
17. Geisler S.A., and Olshan A.F. GSTM1, GSTT1 and the risk of squamous cell carcinoma of the head and neck: a mini-review. Am. J. Epidemiol. 154 (2001) 95-105
18. Hu X., Xia H., Srivastava S.K., Herzog C., Awasthi Y.C., Ji X., Zimniak P., and Singh S.V. Activity of four allelic forms of glutathione S-transferase hGSTP1-1 for diol epoxides of polycyclic aromatic hydrocarbons. Biochem. Biophys. Res. Commun. 238 (1997) 397-402
19. Sundberg K., Johansson A.S., Stenberg G., Widersten M., Seidel A., Mannervik B., and Jernstrom B. Differences in the catalytic efficiencies of allelic variants of glutathione transferase P1-1 towards carcinogenic diol epoxides of polycyclic aromatic hydrocarbons. Carcinogenesis 19 (1998) 433-436
20. Morita S., Yano M., Tsujinaka T., Akiyama Y., Taniguchi M., Kaneko K., Miki H., Fujii T., Yoshino K., Kusuoka H., and Monden M. Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to head-and neck squamous-cell carcinoma. Int. J. Cancer 80 (1999) 685-688
21. Park J.Y., Schantz S.P., Stern J.C., Kaur T., and Lazarus P. Association between GSTP1 polymorphisms and oral cancer risk. Pharmacogenetics 9 (1999) 497-504
22. Park D.J., and Lenz H. Determinants of chemosensitivity in gastric cancer. Curr. Opin. Pharmacol. 6 (2006) 337-344
23. Stoehlmacher J., Park D.J., Zhang W., Groshen S., Tsao-Wei D.D., Yu M.C., and Lenz H.J. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J. Natl. Cancer Inst. 94 (2002) 936-942
24. Stoehlmacher J., Park D.J., Zhang W., Yang D., Groshen S., Zahedy S., and Lenz H.J. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br. J. Cancer 91 (2004) 344-354
25. Nurfadhlina M., Foong K., Teh L.K., Tan S.C., Zaki S.M., and Ismail R. CYP2A6 polymorphisms in Malays, Chinese and Indians. Xenobiotica 36 (2006) 684-692
26. Quiñones L., Lucas D., Godoy J., Cáceres D., Berthou F., Varela N., Lee K., Acevedo C., Martínez L., Aguilera A.M., and Gil L. CYP1A1,CYP2E1 and GSTM1 genetic polymorphisms. The effect of single and combined genotypes on lung cancer susceptibility in Chilean people. Cancer Lett. 174 (2001) 35-44
27. Sikdar N., Mahmud S.K., Paul R.R., and Roy B. Polymorphism in CYP1A1 and CYP2E1 genes and susceptibility to leukoplakia in Indian tobacco users. Cancer Lett. 195 (2003) 33-42
28. Ariyoshi N., Takahashi Y., Miyamoto M., et al. Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C. Pharmacogenetics 10 (2000) 687-693
29. Harries L.W., Stubberns M.J., Forman D., Howard G.C.W., and Wolf C.R. Identification of genetic polymorphisms at the glutathione-S-transferase P1 locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 18 (1997) 641-644
30. Yamanaka H., Nakajima M., Nishimura K., Yoshida R., Fukami T., Katoh M., and Yokoi T. Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted. Eur. J. Pharm. Sci. 22 (2004) 419-425
31. Nakajima M., Fukami T., Yamanaka H., Higashi E., Sakai H., Yoshida R., Kwon J.T., McLeod H.L., and Yokoi T. Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin. Pharmacol. Ther. 80 (2006) 282-297
32. Saarikoski S.T., Reinikainen A.V.M., Anttila S., Karjalainen A., Malaveille C., Vainio H., Husgafvel-Pursiainen K., and Hirvonen A. Combined effect of polymorphic GST genes on individual susceptibility to lung cancer. Int. J. Cancer 77 (1998) 516-521
33. Munafo M.R., Clark T.G., Johnstone E.C., Murphy M.F.G., and Walton R.T. The genetic basis for smoking behavior: a systematic review and meta-analysis. Nicotine Tob. Res. 6 (2004) 583-597
34. Ichikawa W., and Sasaki Y. Challenges in predicting the clinical outcome in S-1-based chemotherapy for gastric cancer patients. Int. J. Clin. Oncol. 13 (2008) 206-211
35. Oguri T., Fujiwara Y., Katoh O., Daga H., Ishikawa N., Fujitaka K., Yamasaki M., Yokozaki M., Isobe T., Ishioka S., and Yamakido M. Glutathione S-transferase-π gene expression and platinum drug exposure in human lung cancer. Cancer Lett. 156 (2000) 93-99
36. Goekkurt E., Hoehn S., Wolschke C., Wittmer C., Stueber C., Hossfeld D.K., and Stoehlmacher J. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)-novel predictors for response and survival in gastric cancer patients. Br. J. Cancer 94 (2006) 281-286
37. Keam B., Im S.A., Han S.W., Ham H.S., Kim M.A., Oh D.Y., Lee S.H., Kim J.H., Kim D.W., Kim T.Y., Heo D.S., Kim W.H., and Bang Y.J. Modified FOLFOX-6 chemotherapy in advanced gastric cancer: results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC Cancer 8 (2008) 148
38. Booton R., Ward T., Heighway J., Ashcroft L., Morris J., and Thatcher N. Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer. J. Thorac. Oncol. 10 (2007) 902-906
39. Peklak-Scott C., Smitherman P.K., Townsend A.J., and Morrow C.S. Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Mol. Cancer Ther. 10 (2008) 3247-3255